W.R. Berkley Corporation Common Stock vs Zimmer Biomet Holdings Inc — how do they compare? W.R. Berkley Corporation Common Stock trades at $74.93 (market cap $27.40B), while Zimmer Biomet Holdings Inc trades at $92.24 (market cap $17.50B). The key difference: W.R. Berkley Corporation Common Stock is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.05%). Which is the better fit depends on your goals — on Pluang, investors hold W.R. Berkley Corporation Common Stock for 0 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| WRB | ZBH | |
|---|---|---|
Market Cap | $27.40B | $17.50B |
Volume | 2,015,378 | 1,890,029 |
Sector | Financials | Health |
52-Week High | $78.10 | $103.98 |
52-Week Low | $63.54 | $79.58 |
Typical Hold Time | 0 Days | 89 Days |
Enterprise Value | $27.64B | $24.57B |
Dividend Yield | 0.54% | 1.05% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zimmer Biomet (ZBH) trades at $92.08, down 0.1% on the day, with a bullish technical outlook supported by moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 8.56%. A quarterly dividend of $0.24 was recently declared, payable in October 2026.
The investment outlook is cautiously optimistic, driven by earnings beats and analyst consensus pointing to upside. Key risks include rising debt levels and competitive pressures. The consensus price target of $103.11 suggests potential appreciation, but investors should weigh margin trends and macroeconomic factors affecting healthcare spending.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
W.R. Berkley Corporation is an insurance holding company that underwrites commercial property and casualty insurance and reinsurance through its Insurance and Reinsurance & Monoline Excess segments.
Read more on WRB →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →